Ladenburg lowered the firm’s price target on Eledon Pharmaceuticals (ELDN) to $20.50 from $28 and keeps a Buy rating on the shares. The firm says the Phase 2 BESTOW RT study completed enrollment four months early.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELDN:
- Eledon Pharmaceuticals Reports Strong Q3 2024 Results
- Eledon Pharmaceuticals reports Q3 EPS (32c), consensus (31c)
- ELDN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Eledon Pharmaceuticals Announces $85 Million Stock Offering
- Eledon Pharmaceuticals Reports Promising Trial Results for Tegoprubart